No consensus on EU-wide review of clinical trial applications
This article was originally published in Scrip
European pharmaceutical industry association EFPIA wants the European Commission to consider allowing centralised review of clinical trial authorisation (CTA) applications. But the procedure, it says, should complement the present regulatory framework and not replace it.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-four guidance documents have been posted on the tracker since its last update.
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.